Camlin Fine Sciences Reports ₹1,723 Cr FY26 Revenue Amidst Cost Pressures

Camlin Fine Sciences recorded total revenue of ₹1,723 crore for the fiscal year 2026, with the fourth quarter contributing ₹424 crore. The company's EBITDA for Q4 FY2026 stood at ₹21 crore.

Reader Takeaway: Positive CFS Europe liquidation offsets margin pressure from raw material inflation and freight costs.

What just happened

Camlin Fine Sciences announced its financial results for the fiscal year ending March 31, 2026. The company reported a total revenue of ₹1,723 crore for FY2026 and ₹424 crore for the fourth quarter (Q4 FY2026). EBITDA for the quarter was ₹21 crore. The company also reported a total debt of ₹670 crore as of March 31, 2026. A non-recurring gain of approximately ₹100 crore was recognized from the liquidation of its European subsidiary, CFS Europe.

Why this matters

The results highlight the impact of external factors like raw material price inflation, particularly phenol, and increased freight costs on the company's profitability. The liquidation of CFS Europe is a significant event, expected to eliminate an annual cash burn of ₹50-60 crore, thereby improving future cash flows. Management's guidance for FY2027, targeting a 12-14% EBITDA margin, signals confidence despite current challenges.

The backstory

Camlin Fine Sciences is a global producer of antioxidants and performance chemicals. The company has been managing raw material price volatility and supply chain disruptions. The acquisition of Vinpai and the ongoing Middle East crisis have added to the operational complexities faced during the quarter.

What changes now

With the liquidation of CFS Europe, the company aims to reduce its cash burn significantly. Management has also decided to stop its diphenol production, opting to import hydroquinone and utilize existing catechol inventory to manage raw material costs. These tactical shifts are aimed at improving operational efficiency and financial performance in the upcoming quarters. The company plans to repay ₹60-70 crore of debt in FY2027 using structured debt and bank finance.

Risks to watch

Margin pressure remains a key concern, with Q4 FY2026 EBITDA margins at 5%. Volatile freight costs and ongoing supply chain issues could continue to impact revenue and working capital. The total debt of ₹670 crore requires careful management and timely repayment.

Peer comparison

While specific peer data isn't provided in the filing, companies in the specialty chemicals sector often face similar challenges with raw material costs and global supply chain disruptions. Camlin Fine Sciences' focus on specific product segments like vanillin, where realizations improved, offers a degree of differentiation.

Context metrics (time-bound)

• FY2026 Total Revenue: ₹1,723 crore
• Q4 FY2026 Revenue: ₹424 crore
• Q4 FY2026 EBITDA: ₹21 crore
• Total Debt (as of March 31, 2026): ₹670 crore
• CFS Europe Liquidation Gain: ~₹100 crore
• Estimated Annual Cash Burn Elimination: ₹50-60 crore
• EBITDA Impact from Middle East Crisis: ~₹30 crore
• FY2027 Debt Repayment Plan: ₹60-70 crore
• FY2027 EBITDA Margin Target: 12-14%
• Q4 Vanillin Realization: Improved to over $12.5

What to track next

Investors should closely monitor the company's ability to achieve its FY2027 EBITDA margin targets, the normalization of freight costs, and the successful integration of the Vinpai acquisition. The management's progress in debt reduction and working capital management will also be crucial indicators.